HCL-GROUP
21.5.2024 14:05:33 CEST | Business Wire | Press release
HCL Group, a global conglomerate, and UpLink, the open innovation platform of the World Economic Forum, announced the third challenge of the Aquapreneur Innovation Initiative, the “Tackling Water Pollution Challenge.” This announcement was made during the 10th World Water Forum in Bali, Indonesia. The application deadline for submission is 31st August 2024. The winners will be announced in January 2025, and the top 10 winners will receive a total financial award of 1.75M CHF. Detailed information and eligibility requirements can be accessed through the following link.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521731615/en/
Sundar Mahalingam, President of Strategy at HCL Corporation, unveils Challenge 3 of the Aquapreneur Innovation Initiative at the World Water Forum in Bali (Photo: Business Wire)
Important Dates to Note |
|
21 May to 31st August 2024 |
Open for submissions |
1st September to 1st November 2024 |
Review and selection process |
January 2025 |
Announcement of the Top Innovators |
The Innovation Challenge aims to empower changemakers who are pioneering groundbreaking technologies, strategies, and approaches to conserve, manage, and protect water resources. HCL has pledged US$15 million over five years till 2027 to bolster entrepreneurs focusing on water-related endeavors. The challenge will focus on the intersection of the quality and environmental impacts of water, with the key aspects including:
-
Preventing contamination of water at source- Source control aims to prevent or minimize the introduction of pollutants and contaminants at their source. Solutions may be aimed at contaminants from industry, agriculture, stormwater etc., and could include real-time monitoring and sensor networks, advanced filtration, and nature-based solutions.
-
Monitoring and treating onsite industrial wastewater- Water is a core component in many industrial processes from manufacturing, cleaning and sanitation, mining, and cooling. Technological solutions offer a way to monitor water quality and reduce water contamination, minimize environmental impacts and move towards zero liquid discharge for industries.
-
Optimising urban infrastructure public water and wastewater treatment systems- Water and wastewater treatment infrastructure upgrades are expensive and the costs are climbing. This area will target a broad range of technological solutions that can unlock value by improving efficiency, reducing costs, and ensuring compliance.
- Offering water quality solutions for households- The convergence of environmental awareness, cost considerations, regulatory pressures, and health concerns is driving the increasing popularity of personal water quality solutions among individuals and households. Technological solutions may include portable water testing, point-of-use water purification, and apps for crowd-sourcing water quality data.
While launching the challenge, Sundar Mahalingam, President of Strategy at HCL Corporation said, "At HCL, we understand the power of innovation, and through our partnership with UpLink, we are empowering Aquapreneurs to scale their solutions and drive meaningful impact. The first two editions of the Aquapreneur Innovation Initiative have demonstrated remarkable success, with participating entrepreneurs showcasing solutions that address critical water challenges. The Aquapreneurs from the first challenge have raised $54.5 million grants and venture capital funding since joining the cohort. This validates the effectiveness of the initiative in nurturing and supporting innovative ideas that address critical water challenges. We are, therefore, thrilled to announce the third challenge, aiming to engage a broader network of Aquapreneur globally.”
John Dutton, Head of UpLink, World Economic Forum, added, “At UpLink, we believe innovation and collaboration are key to overcoming the complex water challenges facing our planet. UpLink and HCL Group will tap into the world’s brightest entrepreneurial minds working in this sector to help minimize the problem of freshwater loss by connecting them to essential resources, experts, and funding. The Tackling Water Pollution Challenge will ensure that the most scalable solutions are deployed to ensure that this vital resource is sustainably available to all.”
Evaluation and selection criteria for 3rd year includes:
-
Business viability
- Demonstrates a financially sustainable business model with a clear revenue approach.
- Presents a funding history and potential for investment.
- Identifies and manages external risks effectively.
- Shows alignment with market demand locally or globally.
-
Has a legal entity and operational plan for financial sustainability.
-
Commitment to Deliver Impact
- Shows sustainable impact benefiting multiple sectors including society and the environment.
- Aligns with long-term water agenda goals.
- Utilizes a robust framework for impact measurement and verification.
-
Transparently tracks metrics and adheres to relevant standards.
-
Solution Novelty and Replicability
- Offers unique aspects in product/service, pricing, partnerships, or business model.
- Provides evidence of concept feasibility and replicability across different contexts.
As water scarcity and pollution continue to pose significant threats to communities and ecosystems globally, the Aquapreneur Innovation Initiative seeks to harness the power of innovation to create sustainable solutions. Selected participants will receive mentorship, funding support, access to networks, media visibility, and other resources to scale their initiatives and maximize their impact.
About HCL
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978, well before its global peers. Today, the HCL enterprise has a presence across varied sectors that include technology, healthcare and talent management solutions and comprises three companies – HCL Infosystems, HCLTech and HCL Healthcare. The enterprise generates annual revenues of over US$13.3 billion with 227,481 employees operating across 60 countries. For further information, visit www.hcl.com
About UpLink
UpLink is the open innovation platform of the World Economic Forum, dedicated to unlocking an ‘entrepreneur revolution’ to support positive systemic change for people and planet. Launched at the Forum’s Annual Meeting in Davos in January 2020 with support from Salesforce and Deloitte, UpLink is now a thriving ecosystem of entrepreneurs, investors and experts, who are collaborating around innovation for the UN Sustainable Development Goals.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521731615/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
